Expression of vascular Notch ligands Delta-like 4 and Jagged-1 in glioblastoma

Histopathology

Volumn 60, Issue 5, 2012, Pages 740-747

  Jubb, Adrian M ^a   Browning, Lisa ^a   Campo, Leticia ^a   Turley, Helen ^a   Steers, Graham ^a   Thurston, Gavin ^b   Harris, Adrian L ^c   Ansorge, Olaf ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b REGENERON PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Delta like ligand 4; Glioblastoma; Jagged 1; Notch; Vascular endothelial growth factor; VEGF

Indexed keywords

BEVACIZUMAB; JAGGED1; NOTCH LIGAND DELTA LIKE 4; NOTCH RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADULT; AGED; BRAIN NEOPLASMS; CALCIUM-BINDING PROTEINS; CEREBROVASCULAR CIRCULATION; DNA, NEOPLASM; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; IN SITU HYBRIDIZATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84858998140     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04138.x     Document Type: Article

References (37)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407; 249-257.
2. Brat DJ, Castellano-Sanchez AA, Hunter SB et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 2004; 64; 920-927.
3. Jubb AM, Buffa FM, Harris AL. Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J. Cell Mol. Med. 2010; 14; 18-29.
4. Ferrara N, Leung DW, Cachianes G, Winer J, Henzel WJ. Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells. Methods Enzymol. 1991; 198; 391-405.
5. Forsythe JA, Jiang BH, Iyer NV et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996; 16; 4604-4613.
6. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res. 2000; 60; 5879-5886.
7. Gorski DH, Beckett MA, Jaskowiak NT et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59; 3374-3378.
8. Lee CG, Heijn M, di Tomaso E et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000; 60; 5565-5570.
9. Wachsberger PR, Burd R, Cardi C et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 2007; 67; 1526-1537.
10. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 1996; 93; 14765-14770.
11. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009; 27; 4733-4740.
12. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 2009; 27; 740-745.
13. Vredenburgh JJ, Desjardins A, Herndon JE II et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 2007; 25; 4722-4729.
14. Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 2010; 116; 3988-3999.
15. Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J. Clin. Oncol. 2010; 28; e91-e93.
16. Sathornsumetee S, Cao Y, Marcello JE et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 2008; 26; 271-278.
17. Noguera-Troise I, Daly C, Papadopoulos NJ et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006; 444; 1032-1037.
18. Ridgway J, Zhang G, Wu Y et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006; 444; 1083-1087.
19. Indraccolo S, Minuzzo S, Masiero M et al. Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Res. 2009; 69; 1314-1323.
20. Hellstrom M, Phng LK, Hofmann JJ et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007; 445; 776-780.
21. Li JL, Sainson RC, Shi W et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 2007; 67; 11244-11253.
22. Williams CK, Segarra M, Sierra Mde L, Sainson RC, Tosato G, Harris AL. Regulation of CXCR4 by the Notch ligand delta-like 4 in endothelial cells. Cancer Res. 2008; 68; 1889-1895.
23. Benedito R, Roca C, Sorensen I et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009; 137; 1124-1135.
24. Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006; 107; 931-939.
25. Jubb AM, Soilleux EJ, Turley H et al. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am. J. Pathol. 2010; 176; 2019-2028.
26. Jubb AM, Turley H, Moeller HC et al. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br. J. Cancer 2009; 101; 1749-1757.
27. Reedijk M, Odorcic S, Zhang H et al. Activation of Notch signaling in human colon adenocarcinoma. Int. J. Oncol. 2008; 33; 1223-1229.
28. Pannuti A, Foreman K, Rizzo P et al. Targeting Notch to target cancer stem cells. Clin. Cancer Res. 2010; 16; 3141-3152.
29. Li JL, Harris AL. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front. Biosci. 2009; 14; 3094-3110.
30. Jakobsson L, Franco CA, Bentley K et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat. Cell Biol. 2010; 12; 943-953.
31. Purow BW, Haque RM, Noel MW et al. Expression of Notch-1 and its ligands, delta-like-1 and jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005; 65; 2353-2363.
32. Patel NS, Dobbie MS, Rochester M et al. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin. Cancer Res. 2006; 12; 4836-4844.
33. Stewart KS, Zhou Z, Zweidler-McKay P, Kleinerman ES. Delta like ligand 4-Notch signaling regulates BM-derived pericyte/vascular smooth muscle cell formation. Blood 2010; 117; 719-726.
34. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat. Rev. Cancer 2006; 6; 626-635.
35. Li Z, Wang J, Gong L, Wen Z, Xu C, Huang X. Correlation of delta-like ligand 4 (DLL4) with VEGF and HIF-1alpha expression in human glioma. Asian Pac. J. Cancer Prev. 2011; 12; 215-218.
36. Jeon HM, Jin X, Lee JS et al. Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling. Genes Dev. 2008; 22; 2028-2033.
37. Rozanov DV, Savinov AY, Williams R et al. Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer. Cancer Res. 2008; 68; 4086-4096.